title: Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating.
abstract: Pompe disease was named after the Dutch pathologist Dr JC Pompe who reported about a deceased infant with idiopathic hypertrophy of the heart. The clinical findings were failure to thrive, generalized muscle weakness and cardio-respiratory failure. The key pathologic finding was massive storage of glycogen in heart, skeletal muscle and many other tissues. The disease was classified as glycogen storage disease type II and decades later shown to be a lysosomal disorder caused by acid alpha-glucosidase deficiency. The clinical spectrum of Pompe disease appeared much broader than originally recognized. Adults with the same enzyme deficiency, alternatively named acid maltase deficiency, were reported to have slowly progressive skeletal muscle weakness and respiratory problems, but no cardiac involvement. The clinical heterogeneity is largely explained by the kind and severity of mutations in the acid alpha-glucosidase gene (GAA), but secondary factors, as yet unknown, have a substantial impact. The Pompe disease mutation database aims to list all GAA sequence variations and describe their effect. This update with 107 sequence variations (95 being novel) brings the number of published variations to 289, the number of non-pathogenic mutations to 67 and the number of proven pathogenic mutations to 197. Further, this article introduces a tool to rate the various mutations by severity, which will improve understanding of the genotype-phenotype correlation and facilitate the diagnosis and prognosis in Pompe disease.
authors.affiliation: Departments of Clinical Genetics and Pediatrics, Erasmus MC, Rotterdam, The Netherlands.
authors.forename: Marian
authors.initials: M
authors.lastname: Kroos
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Pomponio
authors.forename: Laura
authors.initials: L
authors.lastname: van Vliet
authors.forename: Rachel E
authors.initials: RE
authors.lastname: Palmer
authors.forename: Michael
authors.initials: M
authors.lastname: Phipps
authors.forename: Robert
authors.initials: R
authors.lastname: Van der Helm
authors.forename: Dicky
authors.initials: D
authors.lastname: Halley
authors.forename: Arnold
authors.initials: A
authors.lastname: Reuser
mesh_terms: D000818:Animals; D019556:COS Cells; D002522:Chlorocebus aethiops; D006224:Cricetinae; D004252:DNA Mutational Analysis; D030541:Databases, Genetic; D005091:Exons; D020022:Genetic Predisposition to Disease; D006009:Glycogen Storage Disease Type II / Q000235:genetics* / Q000503:physiopathology; D006801:Humans; D007438:Introns; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D012720:Severity of Illness Index; D000520:alpha-Glucosidases / Q000235:genetics* / Q000378:metabolism
chemical_list: C509951:GAA protein, human; D000520:alpha-Glucosidases